• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Relugolix Versus Leuprorelin for the Management of Endometriosis-Associated Pelvic Pain

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Relugolix (REL) is an oral GnRH antagonist medication 
  • Leuprorelin (LEU) is a sustained-released GnRH agonist that downregulates the GnRH receptor 
  • Harada et al. (Fertility and Sterility 2021) evaluated the efficacy and safety of 40-mg REL vs LEU in women with endometriosis-associated pain 

METHODS: 

  • Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study 
    • 42 centers in Japan  
  • Participants 
    • ≥20 years  
    • Regular menstrual cycles (25 to 38 days)  
    • Endometriosis or ovarian endometrioma and pelvic pain 
  • Interventions 
    • REL group: 40 mg of REL, orally administered once a day for 24 weeks 
    • LEU group: 3.75 or 1.88 (body weight <50 kg) mg of LEU, subcutaneously injected every 4 weeks for 24 weeks 
  • Primary outcome 
    • Change in the maximum visual analog scale (VAS) score for pelvic pain from baseline until the end of treatment period (last 28 days of the treatment period including those who completed treatment up to 24 weeks or discontinued treatment early) 
  • Secondary outcomes 
    • Change from baseline to the end of treatment for 
      • Mean VAS score | Menstrual pain | Nonmenstrual pelvic pain (NMPP) | Dyspareunia 

RESULTS: 

  • REL group: 171 participants | LEU group: 164 participants 
  • REL was found to be noninferior to LEU at reducing maximum visual analog scale score for pelvic pain  
    • Changes in the mean (±SD) maximum visual analog scale score 
      • REL: −52.6 ± 1.3 
      • LEU: −57.5 ± 1.4 
  • Ovarian endometrioma also decreased among both treatment groups 
    • REL: –12.26 ± 17.52 cm3  
    • LEU: –14.10 ± 18.81 cm3 
  • Return of menses 
    • REL: Median, 38 days 
    • LEU: Median 68 days 
    • By approximately 4 months, menstruation had returned to almost all patients 
  • Drug-related treatment emergent adverse events (TEAE) with an incidence of >10% for both groups  
    • Hot flushes 
    • Metrorrhagia 
    • Headache 
    • Genital hemorrhage 
  • Discontinuations due to TEAE 
    • REL: 2.9% 
    • LEU: 4.3% 

CONCLUSION: 

  • Relugolix was found to be noninferior to leuprorelin at reducing endometriosis-associated pelvic pain 
  • Both treatment groups experienced similar levels of adverse events 
  • Women in the relugolix group had their menses return earlier than those in the leuprorelin group 
  • The authors state 

The recovery of the serum E2 levels and menstruation after EOT occurred earlier for REL than for LEU, a huge advantage for patients who plan to become pregnant 

In addition, because REL is an oral drug, patients often recover from a TEAE more quickly after stopping treatment 

Learn More – Primary Sources: 

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ENOCA Study Results: Is There a Link Between Endometriosis and Risk for Ovarian Cancer?
Does Elagolix Treatment for Endometriosis Pain Also Reduce Fatigue?
Ablation or Excision for Endometriosis Associated Pain?
Does the Oral GnRH Antagonist Elagolix Improve Endometriosis-Associated Pain?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site